NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
NetraMark Holdings Inc. is poised to advance psychedelic clinical trials using its AI-powered NetraAI platform, following a recent U.S. executive order aimed at accelerating innovation in this field. The company's technology is designed to address the complex analytical challenges associated with psychedelic trials.
NetraMark Holdings Inc., a Canadian AI company, is well-positioned to support psychedelic clinical trials with its NetraAI platform. The U.S. executive order aims to accelerate innovation in this emerging field. Psychedelic trials are analytically demanding due to patient heterogeneity and subjective endpoints. NetraMark's NetraAI platform identifies model-derived subgroups to support hypothesis generation and stratification strategies. The company's approach is grounded in peer-reviewed scientific validation within complex CNS datasets. NetraAI has been applied to a completed Phase II ketamine study, demonstrating an explainable approach to identifying clinically meaningful patient subgroups.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.